These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20108343)

  • 21. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberous sclerosis complex: tumors and tumorigenesis.
    Borkowska J; Schwartz RA; Kotulska K; Jozwiak S
    Int J Dermatol; 2011 Jan; 50(1):13-20. PubMed ID: 21182496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
    Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
    Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal cell carcinoma in patients with tuberous sclerosis.
    Weinblatt ME; Kahn E; Kochen J
    Pediatrics; 1987 Dec; 80(6):898-903. PubMed ID: 3317262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal cell carcinoma associated with tuberous sclerosis: a case report].
    Yasukawa S; Aoshi H; Kyoku I; Uekado Y; Ohkawa T
    Hinyokika Kiyo; 1989 Dec; 35(12):2135-8. PubMed ID: 2694834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
    Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
    Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features.
    Bjornsson J; Short MP; Kwiatkowski DJ; Henske EP
    Am J Pathol; 1996 Oct; 149(4):1201-8. PubMed ID: 8863669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and molecular insights into tuberous sclerosis complex renal disease.
    Siroky BJ; Yin H; Bissler JJ
    Pediatr Nephrol; 2011 Jun; 26(6):839-52. PubMed ID: 21152937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cell carcinoma as significant manifestation of tuberous sclerosis complex.
    Kulkarni S; Uddar M; Deshpande SG; Vaid S; Wadia RS
    J Assoc Physicians India; 2000 Mar; 48(3):351-3. PubMed ID: 11229127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
    Lee L; Sudentas P; Dabora SL
    Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Renal angiomyolipoma and renal cell carcinoma associated with tuberous sclerosis: a case report].
    Sugimoto M; Takamura S
    Hinyokika Kiyo; 1997 Jan; 43(1):33-5. PubMed ID: 9046419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case records of the Massachusetts General Hospital. Case 26-2011. A 7-year-old boy with a complex cyst in the kidney.
    Paul E; Thiele EA; Shailam R; Rosales AM; Sadow PM
    N Engl J Med; 2011 Aug; 365(8):743-51. PubMed ID: 21864169
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting mTOR in renal cell carcinoma.
    Hudes GR
    Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The kidney in the tuberous sclerosis complex.
    Torres VE; King BF; Holley KE; Blute ML; Gomez MR
    Adv Nephrol Necker Hosp; 1994; 23():43-70. PubMed ID: 8154365
    [No Abstract]   [Full Text] [Related]  

  • 39. Sirolimus can promote the disappearance of renal angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
    Dun S; Wang YY; Wan L; Wang QH; Lu Q; Yang XY; Zhang Q; Chen HM; Qiu LP; Zou LP
    World J Pediatr; 2024 Jun; 20(6):602-610. PubMed ID: 37773307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K; Borkowska J; Jozwiak S
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.